Edwards Lifesciences' EVOQUE System Shows Sustained Benefits in Two-Year TRISCEND II Trial Data
Event summary
- Two-year data from the TRISCEND II trial presented at ACC.26 shows significant and sustained patient benefits from Edwards Lifesciences' EVOQUE transcatheter tricuspid valve replacement (TTVR) system.
- Key findings include near elimination of tricuspid regurgitation, improved quality of life, and lower all-cause mortality when accounting for patient crossover.
- The trial involved 1,000+ patients, with 18-month data previously presented at ESC 2025 showing hard endpoint benefits for severe tricuspid regurgitation patients.
- The EVOQUE system is approved in both the US and Europe.
The big picture
Edwards Lifesciences' EVOQUE system is positioning itself as a leading solution for tricuspid regurgitation, a condition with limited treatment options. The sustained benefits demonstrated in the TRISCEND II trial reinforce the strategic importance of transcatheter valve replacement technologies in addressing structural heart disease. The company's focus on innovative solutions and strong clinical evidence is likely to drive further growth in this high-need patient population.
What we're watching
- Market Adoption
- The pace at which the EVOQUE system gains market share in the tricuspid regurgitation treatment space, particularly among the sickest patients.
- Regulatory Dynamics
- Whether the sustained benefits demonstrated in the TRISCEND II trial will lead to expanded approvals or indications for the EVOQUE system.
- Competitive Positioning
- How Edwards Lifesciences will differentiate the EVOQUE system against potential competitors entering the TTVR market.